A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 6.21 USD -1.74%
Market Cap: 757.6m USD

Wall Street
Price Targets

AQST Price Targets Summary
Aquestive Therapeutics Inc

Wall Street analysts forecast AQST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AQST is 10.51 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

Lowest
Price Target
8.08 USD
30% Upside
Average
Price Target
10.51 USD
69% Upside
Highest
Price Target
15.75 USD
154% Upside
Aquestive Therapeutics Inc Competitors:
Price Targets
KOTRA
Kotra Industries Bhd
19% Upside
4015
Jamjoom Pharmaceuticals Factory Company SJSC
14% Upside
600867
Tonghua Dongbao Pharmaceutical Co Ltd
32% Upside
128940
Hanmi Pharm Co Ltd
7% Upside
4516
Nippon Shinyaku Co Ltd
26% Downside
ORNBV
Orion Oyj
14% Upside
603456
Zhejiang Jiuzhou Pharmaceutical Co Ltd
17% Upside

Revenue
Forecast

Revenue Estimate
Aquestive Therapeutics Inc

For the last 7 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -2%. The projected CAGR for the next 4 years is 32%.

-2%
Past Growth
32%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Aquestive Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-64%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AQST's stock price target?
Price Target
10.51 USD

According to Wall Street analysts, the average 1-year price target for AQST is 10.51 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

What is Aquestive Therapeutics Inc's Revenue forecast?
Projected CAGR
32%

For the last 7 years the compound annual growth rate for Aquestive Therapeutics Inc's revenue is -2%. The projected CAGR for the next 4 years is 32%.

Back to Top